Letrozole vs Mifepristone in Medical Termination of Pregnancy A Randomized Trial Analysis

Medical termination of pregnancy (MTP) is a critical aspect of reproductive healthcare, with ongoing research aimed at improving safety, effectiveness, and patient experience. A recent randomized, non-inferiority trial compared letrozole and mifepristone as pre-treatment medications in medical abortion. This blog post explores the trial’s objectives, methodology, key findings, and what they mean for clinical practice and future research.

Comparison of letrozole and mifepristone in medical termination of pregnancy

Objectives and Methodology of the Trial

The trial aimed to determine whether letrozole, an aromatase inhibitor commonly used in fertility treatments, could serve as a safe and effective alternative to mifepristone, the standard pre-treatment drug in medical abortion protocols. Mifepristone works by blocking progesterone receptors, which is essential for maintaining pregnancy, while letrozole reduces estrogen production, potentially affecting the uterine environment differently.

Study Design

• Type: Randomized, non-inferiority trial

• Participants: Women seeking medical termination of pregnancy within the first 9 weeks of gestation

• Intervention Groups:

- Letrozole group received letrozole orally for three days before misoprostol administration.

- Mifepristone group received a single dose of mifepristone followed by misoprostol.

• Primary Outcome: Complete abortion rate without surgical intervention

• Secondary Outcomes: Side effects, time to abortion, patient satisfaction, and safety profiles

  
  

The non-inferiority design meant the trial tested if letrozole was not significantly worse than mifepristone by a pre-specified margin, focusing on whether letrozole could be a viable alternative.

Key Results and Clinical Implications

The trial enrolled over 400 participants, evenly split between the two groups. The main findings included:

• Complete abortion rates: Letrozole achieved a 92% success rate, while mifepristone had a 95% success rate. The difference fell within the non-inferiority margin, indicating letrozole was not significantly less effective.

• Time to abortion: Women in the letrozole group experienced a slightly longer median time to complete abortion (about 24 hours longer) compared to the mifepristone group.

• Side effects: Both groups reported similar rates of common side effects such as bleeding, cramping, nausea, and vomiting. No serious adverse events were linked to either medication.

• Safety: No significant differences in safety profiles were observed, supporting the use of letrozole as a safe alternative.

  
  

These results suggest that letrozole could be considered when mifepristone is unavailable or contraindicated. The slightly longer time to abortion with letrozole may require counseling patients about what to expect.

Effectiveness and Safety Comparison

Effectiveness

• Mifepristone remains the gold standard with a slightly higher success rate and faster abortion process.

• Letrozole shows comparable effectiveness, making it a promising alternative, especially in settings where mifepristone access is limited.

  
  

Safety

• Both drugs demonstrated strong safety profiles.

• Side effects were mild to moderate and transient.

• No increase in serious complications was observed with letrozole.

  
  

This comparison highlights that letrozole can expand options for medical abortion without compromising patient safety or treatment success.

Patient Experiences and Preferences

Patient feedback collected during the trial revealed important insights:

• Pain and bleeding: Most participants reported manageable pain and bleeding, with no significant difference between groups.

• Emotional response: Women appreciated having an alternative option, especially those who had concerns about mifepristone.

• Convenience: Letrozole’s multi-day dosing was seen as less convenient compared to the single-dose mifepristone regimen.

• Counseling needs: Clear communication about the expected timeline and side effects was crucial for patient satisfaction.

  
  

These findings emphasize the importance of personalized care and informed decision-making in medical abortion.

Future Research Directions

While this trial provides valuable data, several questions remain for future studies:

• Long-term outcomes: Research on reproductive health and psychological effects after using letrozole in abortion protocols.

• Broader populations: Trials including women with different gestational ages, comorbidities, or in diverse healthcare settings.

• Cost-effectiveness: Economic analyses comparing letrozole and mifepristone, especially in low-resource environments.

• Combination protocols: Investigating whether combining letrozole with other agents could improve efficacy or reduce side effects.

  
  

Further research will help refine medical abortion protocols and improve access to safe, effective care worldwide.

Referenece:

The use of letrozole or mifepristone for pre‐treatment of medical termination of pregnancy: A randomized, non‐inferiority trial

Teong ACA, Wong TTC, Soe NN, et al. The use of letrozole or mifepristone for pre-treatment of medical termination of pregnancy: A randomized, non-inferiority trial. Int J Gynecol Obstet. 2026;00:1-9. doi:10.1002/ijgo.71104